Daily Cardiology Research Analysis
Three impactful cardiology papers stand out today: a PROSPERO-registered IPD meta-analysis of RCTs shows complete revascularization in STEMI with multivessel disease reduces 5-year mortality and MACE; pooled secondary analyses from STEP-HFpEF demonstrate semaglutide improves 6-minute walk distance and symptoms across baseline functional capacity; and a nationwide registry analysis indicates transferrin saturation <20% best identifies iron deficiency linked to worse outcomes across HF phenotypes.
Summary
Three impactful cardiology papers stand out today: a PROSPERO-registered IPD meta-analysis of RCTs shows complete revascularization in STEMI with multivessel disease reduces 5-year mortality and MACE; pooled secondary analyses from STEP-HFpEF demonstrate semaglutide improves 6-minute walk distance and symptoms across baseline functional capacity; and a nationwide registry analysis indicates transferrin saturation <20% best identifies iron deficiency linked to worse outcomes across HF phenotypes.
Research Themes
- Revascularization strategy in multivessel STEMI
- Metabolic therapy for obesity-related HFpEF
- Refining iron deficiency definitions across HF phenotypes
Selected Articles
1. Complete revascularization in patients with acute myocardial infarction and multivessel disease: Pooled analysis of Kaplan-Meier-derived individual-patient-data.
In a PROSPERO-registered systematic review and IPD meta-analysis of 9 RCTs (n=9,658), complete revascularization in hemodynamically stable acute MI (mostly STEMI) reduced 5-year MACE, all-cause and cardiovascular mortality, MI, and unplanned revascularization versus incomplete revascularization. These findings strengthen recommendations for complete revascularization and suggest a survival benefit.
Impact: Resolves long-standing uncertainty about survival benefits of complete revascularization in multivessel STEMI using robust IPD methods across RCTs. It has immediate relevance to guideline-directed PCI strategies.
Clinical Implications: For hemodynamically stable STEMI with multivessel disease, prefer complete revascularization (either during index procedure or staged) to reduce long-term mortality and MACE. Use these data to inform patient counseling and system-level quality metrics.
Key Findings
- Across 9 RCTs (n=9,658), complete revascularization lowered 5-year MACE (HR 0.59; 95% CI 0.54–0.66; P<.001).
- All-cause mortality was reduced with complete revascularization (HR 0.64; 95% CI 0.56–0.72; P<.001).
- Cardiovascular death (HR 0.82; 95% CI 0.71–0.95; P=.008), MI (HR 0.69; 95% CI 0.55–0.87; P<.001), and unplanned revascularization (HR 0.62; 95% CI 0.54–0.71; P<.001) were all lower.
Methodological Strengths
- PROSPERO-registered systematic review with RCT-only evidence and long-term follow-up.
- Reconstructed individual patient time-to-event data from Kaplan–Meier curves enabling hazard ratio estimation.
Limitations
- Reconstructed IPD rather than access to original raw patient-level datasets.
- Potential heterogeneity in timing/strategy of complete revascularization across trials; trials excluded cardiogenic shock.
Future Directions: Define optimal timing (immediate vs staged), patient subgroups most likely to benefit, and cost-effectiveness; evaluate applicability to patients with shock or complex anatomy.
Complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease reduces major adverse cardiac events (MACE) compared with incomplete revascularization, although whether survival is improved is uncertain. For this systematic review and meta-analysis, all randomized trials of complete vs incomplete revascularization in patients with acute MI without cardiogenic shock were identified from PubMed, Scopus, Web of Science, and Cochrane Library databases from inception to December 31, 2024. The primary and major secondary endpoints were MACE and all-cause mortality derived from reconstructed time-to-event individual-patient-data from published Kaplan-Meier curves. Additional outcomes included cardiovascular mortality, MI, and unplanned repeat revascularizations. Outcomes were expressed as hazard ratios with 95% confidence intervals. This study was registered with the PROSPERO (number, CRD42023415428). A total of 9 randomized trials with 9,658 patients (86.8% with STEMI) were identified among whom 4,671 (48.4%) patients had complete revascularization. Patients with complete revascularization had a lower 5-year risk of MACE (HR: 0.59, 95% CI: 0.54 to 0.66, P < .001) compared with incomplete revascularization. Complete revascularization was also associated with lower 5-year risks of all-cause mortality (HR: 0.64, 95% CI: 0.56 to 0.72, P < .001), cardiovascular mortality (HR: 0.82, 95% CI: 0.71 to 0.95, P = .008), MI (HR: 0.69, 95% CI: 0.55 to 0.87, P < .001), and unplanned repeat revascularizations (HR: 0.62, 95% CI: 0.54 to 0.71, P < .001). Complete revascularization results in lower risks of all-cause and cardiovascular mortality, MI, unplanned repeat revascularizations and MACE in patients with acute MI and multivessel disease. These results support current guidelines recommending CR in hemodynamically stable patients with STEMI, emphasizing that this approach may improve survival.
2. Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.
Across 1,145 patients with obesity-related HFpEF, semaglutide improved 6-minute walk distance versus placebo by 14.6 m at 20 weeks and 17.1 m at 52 weeks, with consistent benefits across subgroups. Semaglutide also improved KCCQ-CSS, reduced body weight and CRP, and lowered NT-proBNP, with greater weight loss correlating with larger 6MWD gains.
Impact: Demonstrates clinically meaningful, early, and consistent improvements in functional capacity and symptoms with semaglutide across baseline exercise function in obesity-related HFpEF, informing therapy selection and patient counseling.
Clinical Implications: Consider semaglutide for obese HFpEF patients to improve functional capacity and symptoms; benefits can appear by 20 weeks and are not limited to those with higher baseline 6MWD. Integrate with comprehensive weight and congestion management.
Key Findings
- Semaglutide improved 6MWD vs placebo at 20 weeks (Δ 14.6 m; 95% CI 8.6–20.7; P<0.0001) and 52 weeks (Δ 17.1 m; 95% CI 9.2–25.0; P<0.0001).
- Benefits were consistent across all prespecified subgroups with no significant interactions by baseline 6MWD.
- Semaglutide increased KCCQ-CSS, reduced body weight and CRP, improved hierarchical composite outcomes, and lowered NT-proBNP; greater weight loss correlated with larger 6MWD improvements.
Methodological Strengths
- Prespecified secondary analysis pooling randomized, placebo-controlled STEP-HFpEF trials.
- Consistent effects across subgroups with multiple convergent endpoints (functional, symptomatic, biomarker).
Limitations
- Secondary analysis; 6MWD changes were not the sole primary outcome across trials.
- Follow-up limited to 52 weeks; generalizability to non-obese HFpEF or diverse care settings requires caution.
Future Directions: Elucidate weight-independent mechanisms, assess longer-term clinical events (HF hospitalizations, mortality), and evaluate combination strategies with SGLT2 inhibitors and exercise training.
BACKGROUND: Exercise function quantified by 6-minute walk distance (6MWD) is severely impaired in patients with heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: This prespecified secondary analysis of pooled data from the STEP-HFpEF Program (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) examined factors associated with impaired exercise function at baseline, detailed effects of semaglutide on 6MWD, and on other key trial endpoints according to baseline 6MWD in patients with HFpEF. METHODS: Associates of 6MWD were assessed at baseline, and effects of semaglutide on 6MWD were evaluated at early (20 weeks) and final (52 weeks) time points, across subgroups, and according to the magnitude of weight loss achieved. Effects of semaglutide on the dual primary (changes in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score [KCCQ-CSS] and body weight) and secondary/exploratory endpoints were contrasted by tertiles of baseline 6MWD. RESULTS: The authors randomized 1,145 patients to semaglutide or placebo. Compared with patients who had obesity-related HFpEF and higher 6MWD, those with lower 6MWD were older and had lower KCCQ-CSS, higher body mass index and waist circumference, greater systemic inflammation (higher C-reactive protein), and more severe congestion (higher N-terminal pro-B-type natriuretic peptide, more diuretic use). Treatment with semaglutide increased 6MWD compared with placebo, an effect apparent at 20 weeks (treatment difference 14.6 m [95% CI: 8.6-20.7 m]; P < 0.0001) that was maintained at 52 weeks (treatment difference 17.1 m [95% CI: 9.2-25.0 m]; P < 0.0001). Increases in 6MWD with semaglutide (vs placebo) were similar across all relevant subgroups, with no significant interactions. Treatment with semaglutide increased KCCQ-CSS and reduced body weight, reduced C-reactive protein, improved the hierarchical composite (death, heart failure events, change in KCCQ-CSS and 6MWD), and reduced N-terminal pro-B-type natriuretic peptide across the spectrum of baseline 6MWD (all P CONCLUSIONS: In patients with obesity-related HFpEF, impaired 6MWD is most strongly associated with excess adiposity, congestion, and inflammation. Semaglutide-mediated improvements in HF-related symptoms, physical limitations, and exercise function were consistent across the spectrum of baseline 6MWD, observed as early as 20 weeks after the initiation of treatment, preceding maximal weight loss. The effects were consistent across subgroups. There was strong correlation between greater magnitude of weight loss and greater improvements in 6MWD. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF], NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM], NCT04916470).
3. Iron Deficiency Definitions in Heart Failure Across Ejection Fraction Phenotypes: Prevalence, Symptoms, and Cause-Specific Outcomes.
In 20,673 Swedish HF patients across EF phenotypes, iron deficiency by TSAT <20% and IRONMAN criteria was most strongly associated with worse symptoms, HR-QoL, and cause-specific outcomes, including mortality and hospitalizations, especially in HFpEF. Ferritin <100 μg/L alone was not associated with outcomes.
Impact: Refines the operational definition of iron deficiency in HF, identifying TSAT <20% as the most prognostically informative criterion and guiding risk stratification and trial design.
Clinical Implications: Adopt TSAT <20% as a preferred marker for identifying high-risk iron deficiency across HF phenotypes; ensure iron panels include TSAT to guide IV iron eligibility and monitoring.
Key Findings
- ID prevalence varied by definition: 49% (guidelines), 53% (IRONMAN), 36% (TSAT <20%), 37% (ferritin <100 μg/L), with highest rates in HFpEF.
- TSAT <20% and IRONMAN criteria had the strongest independent associations with mortality and HF/cardiovascular/noncardiovascular hospitalizations; ferritin <100 μg/L showed no outcome association.
- Associations for TSAT <20% and IRONMAN criteria were stronger in HFpEF for outcomes including HF hospitalization (P interaction <0.05).
Methodological Strengths
- Large, contemporary national HF registry with 20,673 patients spanning HFrEF, HFmrEF, and HFpEF.
- Comparative assessment of four operational iron deficiency definitions with adjusted analyses for symptoms, HR-QoL, and cause-specific outcomes.
Limitations
- Observational design with potential residual confounding; causality cannot be inferred.
- Ferritin and TSAT may be affected by inflammation and assay variability; timing and frequency of measurements were registry-based.
Future Directions: Randomized trials using TSAT <20% to select candidates for IV iron across EF phenotypes, especially HFpEF; dynamic monitoring strategies for iron status over time.
BACKGROUND: How iron deficiency (ID) is defined in heart failure (HF) may affect ID prevalence, associated prognosis, and achievable intravenous iron benefit. OBJECTIVES: This study assessed 4 definitions of ID in heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) and evaluated prevalence, associated health-related quality of life (HR-QoL), symptoms, and cause-specific morbidity and mortality. METHODS: Patients enrolled in the Swedish HF Registry from 2017 to 2023 were included. ID was defined as follows: 1) in current HF guidelines; 2) in the IRONMAN (Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency) trial; 3) with transferrin saturation (TSAT) <20%; and 4) with a ferritin value <100 μg/L. RESULTS: Of 20,673 patients (median age 74 years [Q1-Q3: 65-80 years]; 32% female), 49% fulfilled guideline ID criteria (HFrEF, 48%; HFmrEF, 48%; HFpEF, 54%), 53% fulfilled IRONMAN criteria (HFrEF, 52%; HFmrEF, 52%; HFpEF, 59%), 36% had TSAT <20% (HFrEF, 36%; HFmrEF, 34%; HFpEF, 41%), and 37% has a ferritin level <100 μg/L (HFrEF, 35%; HFmrEF, 37%; HFpEF, 42%). All definitions were independently associated with worse symptoms, and all except ferritin <100 μg/L were associated with worse HR-QoL. TSAT <20% and IRONMAN ID criteria were independently associated with a higher risk of all outcomes, including cardiovascular or all-cause death and HF or all-cause/cardiovascular/noncardiovascular hospitalizations. Guidelines-defined ID was independently associated only with outcomes containing HF hospitalizations or total all-cause hospitalizations, and ferritin <100 μg/L was associated with no outcome. TSAT <20% and IRONMAN ID criteria had stronger associations in HFpEF for outcomes containing HF hospitalization (P interaction < 0.05). TSAT <20% showed the greatest prognostic associations and discrimination. CONCLUSIONS: Irrespective of definition, ID was highly prevalent (highest in HFpEF) and independently associated with worse symptoms or HR-QoL. ID defined as TSAT <20% showed the strongest associations with outcomes, including mortality and HF or cardiovascular/noncardiovascular hospitalizations, likely representing the preferred definition with which to enroll a higher-risk group in trials.